09:55 Chair’s opening remarks and welcome form PRWeek

John Harrington, Editor, PRWeek

10:00 How 2020 brought change and collaboration to the world of Pharma and Healthcare

Keynote presentation

  • How has the industry responded to the pandemic, and how has this translated to policy change?
  • Will the newly forged relationships between Public Health, Public affairs and Pharma affect the way drug messaging is created in 2021?
  • What have communications professionals learned about working together and breaking down silos during the pandemic?

Simon Enright, Director of Communications, NHS England
Massimiliano Di Domenico, Vice President Government Affairs, GSK
Danny Buckland, Freelance Healthcare Journalist
Rachel Rowson, Head of Health Innovation, MHP

10:45 Session break
10:55 Rising to the challenge: How the industry can build vaccine confidence

Keynote presentation

  • How the public’s understanding of vaccines have changed over the past six months
  • The need to build trust with BAME communities
  • How we as healthcare communicators get our societies and economies open again
Annalise Cody, EMEA President, W20 Group

11:15 Session break
11:30 How has the pandemic transformed the role for communications in healthcare
  • Why the pandemic has allowed for more innovation in the NHS in one year than has happened over the past decade
  • Adapting to delivering healthcare virtually and the rise of in-home medication
  • How collaboration with pharma companies has set a new precedent that will fundamentally improve the future of healthcare
Simon Enright, Director of Communications, NHS England
12:00 Networking Lunch
13:30 How can Pharma companies deliver more personalised, targeted communications?
  • Getting a clear and true understanding of the different socio-demographic groups in the UK
  • Building a new strategy that is tailored to the different groups and linking it with business priorities
  • Changing internal systems and processes to deliver it

David Flynn, Head of Public Relations, Roche

13:55 Session break
14:05 Will internal comms take center stage at pharma companies in 2021?
  • How have internal comms teams within pharma and healthcare providers changed in the past year?
  • Is it possible to keep your workforce engaged in an atmosphere of constant change and uncertainty?
  • What are the core tenets of good messaging and comms when you have a workforce that are experiencing burnout and isolation?

Avril Fudge, Communications and PR Lead EMEA, Accord Healthcare

14:25 Session break
14:30 Advantage Hers Case Study: Supporting the unmet health needs of women with serious chronic diseases
  • What are the benefits of an equality-based care approach?
  • Why is a focus on the gender disparities faced by women living with chronic inflammatory diseases important?
  • How is the Advantage Hers campaign helping to address these unmet needs, and why has collaboration been so critical to its success?

Leah Peyton, Director and Healthcare Lead, Europe, Ruder Finn
Andrea L. Christopher, Global Communications Lead, Immunology, UCB Inc

15:00 Has the pandemic presented the pharmaceutical industry with a unique opportunity to redefine its purpose and role in society?

Panel discussion

  • What are the key principles that pharmacomms professionals must bear in mind when talking about their brand’s purpose?
  • Can some businesses still be in danger of purpose washing?
  • Are pharma companies communicating their Covid response effectively? Could this messaging be better aligned to an overall purpose strategy?

Emma Sergeant, President Europe DAS Group of Companies, Omnicom
Lucie Harper, Global Practice Leader, W2O Group
Avril Fudge, Communications and PR Lead EMEA, Accord Healthcare

15:45 Session break
16:00 Will pharmaceutical companies help to lessen the impact of reduced funding on patient groups and charities?
  • Why certain groups feel left behind
  • What can pharmaceutical companies and the wider healthcare industry do to re-engage with patients who feel that their interests have been overshadowed by the pandemic?
  • Is there a need for pharma companies to assist with patient group funding, and how can this be managed in the right way so that patient groups maintain their independence?
Clara MacKay, CEO, World Ovarian Cancer Coalition
Alex Wyke, CEO, Patient View
Helen Rowntree, Director of Research, Services and Engagement, Blood Cancer UK
Jenny Blainey, Director, Hanover Health
Chair: Danny Buckland, Freelance Healthcare Journalist
16:30 Chair’s closing remarks

John Harrington, Editor, PRWeek

Speaking opportunities
Please contact Benita on +44 (0)20 8267 3128 or .

Sponsorship and exhibition opportunities
Please contact Steve on +44 (0)20 8267 8092 or

General enquires
Please call +44 (0)20 8267 4011 or email